Status:

COMPLETED

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

Lead Sponsor:

Essentialis, Inc.

Collaborating Sponsors:

Cetero Research, San Antonio

Conditions:

Hypertriglyceridmia

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

Once a day oral administration with DCCR is the optimal dosing regimen

Detailed Description

POPULATION The population will consist of generally healthy subjects with elevated fasting triglyceride levels in the range of ≥ 150 mg/dL and ≤ 1500 mg/dL at the Screening Visit. Number of Subjects ...

Eligibility Criteria

Inclusion

  • Basic requirements
  • Healthy male and female subjects 18 to 75 years of age, inclusive at the time of dosing
  • Body mass index (BMI) between 22 and 35 kg/m2
  • Specific laboratory test results
  • Fasting triglyceride ≥ 150 mg/dL and ≤ 1500 mg/dL
  • Fasting glucose ≤ 110 mg/dL
  • HbA1c ≤ 6.0 %

Exclusion

  • Medications: recent, current, anticipated
  • Thyroid hormones or preparations within 1 month prior to Screening Visit (except in subjects on stable dose of replacement therapy for at least 1 month)
  • Thiazide diuretics within 2 weeks prior to Screening Visit
  • History of allergic reaction or significant intolerance to:
  • Diazoxide
  • Thiazides
  • Sulfonamides
  • Lifestyle changes
  • Subjects intending to change exercise habits, and/or quit smoking
  • Specific diagnoses, medical conditions and history
  • Known type I or III hyperlipidemia
  • Known type 1 DM
  • Known type 2 DM
  • Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the investigational drug, according to the Investigator
  • Specific laboratory test results
  • Any relevant biochemical abnormality interfering with the assessments of the investigational drug

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2010

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT01211860

Start Date

October 1 2010

End Date

November 1 2010

Last Update

January 10 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cetero

Fargo, North Dakota, United States, 58104